by: Parent Project Muscular Dystrophy
NS Pharma recently joined PPMD for a community webinar to share an overview of two of the company’s new exon skipping trials: Brogidirsen (exon 44) and NS-050/NCNP-03 (exon 50).
Vamshi Rao, MD, discussed these two new clinical trials for individuals with Duchenne who are amenable to either exon 44 or exon 50 skipping. The NS Pharma team answered questions from the community on a variety of topics, as well as touched on the company’s plans for future drug development.
